The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark S. Forman, Marissa F. Dockendorf(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthew D. Troyer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric M. Parker(University of New Hampshire), Britta A. Mattson(United States Military Academy), Michael Egan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stanford S. Jhee(PAREXEL International (United Kingdom)), Michael Tanen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathleen Cox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared N. Cumming(Merck & Co., Inc., Rahway, NJ, USA (United States)), Huub Jan Kleijn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), John Palcza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Hodgson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wěi Li(First Affiliated Hospital of Xi'an Jiaotong University), Xia Chen(First People's Hospital of Foshan), Hong Mei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Larry Ereshefsky(PAREXEL International (United Kingdom)), Jack Tseng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Julie A. Stone(Merck & Co., Inc., Rahway, NJ, USA (United States))
Science Translational Medicine
November 2, 2016
Cited by 416


Related Papers